
ICON Public Limited Company Revenue | ICLR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ICON Public Limited Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.25 B | 8.19 B | 8.05 B | 7.74 B | 5.48 B | 2.8 B | 2.81 B | 2.6 B | 1.76 B | 1.67 B | 1.57 B | 1.5 B | 1.34 B | 1.12 B | 946 M | 900 M | 888 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.25 B | 888 M | 3.39 B |
Quarterly Revenue ICON Public Limited Company
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2009-Q4 | 2008-Q4 | 2007-Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.02 B | 2.06 B | 2.03 B | 2.11 B | 2.08 B | 2.04 B | 2.02 B | 2.06 B | 2.04 B | 2.04 B | 2.04 B | 2.04 B | 2.04 B | 2.01 B | 1.97 B | 1.96 B | 1.94 B | 1.94 B | 1.9 B | 1.89 B | 1.87 B | 871 M | 858 M | 760 M | 702 M | 620 M | 715 M | 725 M | 710 M | 695 M | 675 M | 679 M | 655 M | 642 M | 620 M | 455 M | 440 M | 431 M | 432 M | - | 420 M | 411 M | 401 M | - | 395 M | 389 M | 388 M | - | 388 M | 376 M | 350 M | 345 M | 340 M | 334 M | 317 M | 300 M | 286 M | 277 M | 252 M | 243 M | 241 M | 233 M | 229 M | 900 M | 888 M | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.11 B | 229 M | 1.01 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | ||
|
Senseonics Holdings
SENS
|
35.3 M | $ 9.76 | -3.99 % | $ 407 M | ||
|
Sotera Health Company
SHC
|
1.16 B | $ 16.27 | 1.34 % | $ 4.62 B | ||
|
Co-Diagnostics
CODX
|
622 K | $ 0.2 | 1.99 % | $ 266 K | ||
|
Precipio
PRPO
|
24 M | $ 18.8 | -1.93 % | $ 30.2 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | ||
|
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 29.82 | -0.23 % | $ 28.3 B | ||
|
DarioHealth Corp.
DRIO
|
22.4 M | $ 1.42 | 23.48 % | $ 5.66 M | ||
|
Thermo Fisher Scientific
TMO
|
44.6 B | $ 691.66 | 0.71 % | $ 261 B | ||
|
Myriad Genetics
MYGN
|
824 M | $ 5.54 | -0.09 % | $ 513 M | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.04 | 2.93 % | $ 5.35 M | ||
|
RadNet
RDNT
|
2.04 B | $ 72.01 | -3.88 % | $ 5.41 B | ||
|
QIAGEN N.V.
QGEN
|
2.09 B | $ 49.57 | -0.37 % | $ 10.8 B | ||
|
NeoGenomics
NEO
|
727 M | $ 15.31 | 0.36 % | $ 1.96 B | ||
|
OPKO Health
OPK
|
148 M | $ 1.7 | 4.63 % | $ 1.28 B | ||
|
Pacific Biosciences of California
PACB
|
160 M | $ 1.85 | 1.65 % | $ 555 M | ||
|
Neogen Corporation
NEOG
|
870 M | $ 11.08 | 1.61 % | $ 2.41 B | ||
|
Personalis
PSNL
|
69.6 M | $ 14.97 | 1.15 % | $ 1.34 B | ||
|
Quidel Corporation
QDEL
|
1.66 B | $ 9.62 | -2.53 % | $ 405 M | ||
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M | ||
|
Neuronetics
STIM
|
149 M | $ 1.25 | -1.95 % | $ 82.4 M | ||
|
Trinity Biotech plc
TRIB
|
61.6 M | $ 5.83 | -3.08 % | $ 2.09 B | ||
|
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
7.66 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | ||
|
Exagen
XGN
|
66.6 M | $ 3.91 | 3.99 % | $ 84.3 M | ||
|
VolitionRx Limited
VNRX
|
1.73 M | $ 0.18 | -4.72 % | $ 22.6 M | ||
|
Waters Corporation
WAT
|
932 M | $ 466.25 | 3.66 % | $ 27.8 B | ||
|
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | ||
|
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
137 M | $ 26.17 | 1.08 % | $ 586 M | ||
|
Twist Bioscience Corporation
TWST
|
459 M | $ 116.3 | 3.84 % | $ 7.28 B | ||
|
Organovo Holdings
ONVO
|
131 K | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
30.2 M | - | -16.95 % | $ 1.54 M | ||
|
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | ||
|
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | ||
|
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | ||
|
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M | ||
|
DexCom
DXCM
|
4.66 B | $ 82.53 | 0.6 % | $ 32.2 B | ||
|
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | ||
|
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | ||
|
Quotient Limited
QTNT
|
38.5 M | - | -11.32 % | $ 1.1 M |